Literature DB >> 11237496

Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.

H Petrowsky1, I Sturm, O Graubitz, D A Kooby, E Staib-Sebler, C Gog, C H Köhne, T Hillebrand, P T Daniel, Y Fong, M Lorenz.   

Abstract

AIMS: The liver is a frequent site of metastases from colorectal cancer. While these lesions are potentially amenable to surgical resection, they are usually very aggressive, and recurrence is frequent. Mutations of the proto-oncogene K- ras are thought to impart a strong growth signal to tumour cells and are closely associated with the development of malignancies of the colon and rectum. Hepatic metastases from colorectal cancer have notably elevated proliferative rates. The present study was performed to investigate the relationship between proliferation or K- ras mutation and prognosis following curative resection of colorectal liver metastases.
METHODS: Colorectal liver metastases from 41 patients undergoing curative hepatic resection were examined for proliferation status and presence of K- ras mutations. The proliferative activity was assessed by Ki-67 immunohistochemistry. DNA from the same tissue samples was screened for point mutations in codon 12 of the K- ras gene using a novel microplate-based allelic-specific hybridization assay. Ki-67 scores and K- ras status were then related with patient survival as determined through retrospective analysis.
RESULTS: Median survival was 40 months. Patients with high Ki-67 scores (> or = 50%) had significantly shorter median survival compared with those with low scores (30 vs 44 months, log-rank P=0.02). A high Ki-67 score was an independent negative prognostic factor by multivariate regression analysis (relative risk=3.04, P=0.036). K- ras point mutations were detected in 6/41 patients (15%), but mutational status did not correlate with Ki-67 score or survival.
CONCLUSIONS: These findings suggest that the tumour proliferative index is a useful predictor of aggressive tumour behaviour and an indicator of patient survival. The presence of K- ras mutations does not appear to correlate with tumour proliferation status or patient survival. Copyright Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237496     DOI: 10.1053/ejso.2000.1029

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  32 in total

1.  High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma.

Authors:  Thomas Ihmann; Jian Liu; Wolfgang Schwabe; Peter Häusler; Detlev Behnke; Hans-Peter Bruch; Rainer Broll; Ute Windhövel; Michael Duchrow
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

2.  Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases.

Authors:  J H Cui; U Krueger; D Henne-Bruns; B Kremer; H Kalthoff
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases.

Authors:  M López-Gómez; J Moreno-Rubio; I Suárez-García; P Cejas; R Madero; E Casado; A Jiménez; M Sereno; C Gómez-Raposo; F Zambrana; M Merino; D Fernández-Luengas; J Feliu
Journal:  Clin Transl Oncol       Date:  2014-07-25       Impact factor: 3.405

4.  Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases.

Authors:  Hiromitsu Hayashi; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Naomi Yokoyama; Takaaki Higashi; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Hideo Baba
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

5.  The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Authors:  Guro Aune; Astrid K Stunes; Solveig Tingulstad; Oyvind Salvesen; Unni Syversen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2011-06-11

6.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

Review 7.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

8.  Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?

Authors:  Nazım Emrah Koçer; Fazilet Kayaselçuk
Journal:  Target Oncol       Date:  2013-04-16       Impact factor: 4.493

Review 9.  Surgery for colorectal liver metastases: The evolution of determining prognosis.

Authors:  Gaya Spolverato; Aslam Ejaz; Nilo Azad; Timothy M Pawlik
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

10.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.